Sprout Social enters the week before its next scheduled event with an unusual combination of signals — short sellers have abandoned positions at pace, the stock has jumped 31% in a month, and yet company insiders have not stopped selling.
The clearest story in the data is the collapse in short positioning after Q1 earnings. Short interest as a percentage of the free float fell from roughly 12% to 9.3% in a single week — a 21% drop in shares short over seven days. That is the biggest weekly unwind in the dataset. The catalyst was an earnings print on May 7 that sent the stock up over 16% in a day, a move large enough to flush out a meaningful portion of the short book. Days to cover, per the latest FINRA report, ran at 3.8 — not trivial, and the rapid unwind suggests some of that covering was involuntary rather than strategic. Short score has tracked the move, slipping from 50.7 to 46.9 this week, crossing below the neutral midpoint as the market-wide pressure on longs eased and bears retreated.
Borrow conditions tell a quiet story. Cost to borrow is running at around 0.45%, down 14% on the week and near the low end of its recent range — the brief spike toward 0.94% in late April has fully reversed. Lending availability is loose, with utilization at just 6.25% against a 52-week high of 8.5%. There are plenty of shares available for anyone wanting to rebuild a short position. Options positioning reinforces the bullish lean: the put/call ratio is 0.39, well below its 20-day average of 0.79, reflecting a market that is buying calls rather than hedging with puts. The contrast with April is stark — the PCR ran above 3.0 through much of that month, near its 52-week high, before collapsing as the earnings rally took hold.
The Street's view is mixed but directionally cautious. Barclays, the most active firm in recent months, raised its target to $9 last Monday after maintaining Overweight through the volatility — a sign of renewed conviction after having cut to $8 in April. Goldman Sachs sits at Neutral with an $8 target set in March, and KeyBanc maintains an Underweight call with a $6 floor — the lone explicit bear. The mean price target is $9.50 against the current price of $6.55, implying a theoretical 45% gap, though targets have been moving sharply in both directions this year and that gap partly reflects the stock's dramatic slide from above $25 in late 2025. Valuation has re-rated with the price: the price-to-book ratio has risen 0.24x over the past 30 days, and the P/E has added 1.1 turns. EPS momentum scores in the 61st to 70th percentile range, and the 12-month forward EPS growth rank is at the 72nd percentile — suggesting the earnings trajectory has stabilised more than the stock's history would imply.
Insider activity is the note of caution that sits uneasily with the bullish short-term setup. Founder and Executive Chairman Justyn Howard sold 40,000 shares on May 11 at an average around $6.58 — the third disposal of roughly 40,000 shares in a rolling programme stretching back through March and April. CEO Ryan Barretto sold earlier in the period, and CFO Joseph Del Preto sold in early March. The aggregate net outflow over the past 90 days totals approximately 243,000 shares across these transactions. These are programme-style sales rather than one-off block disposals, but the persistence — selling at $5.03, $5.96, $6.76, $7.37, and now $6.58 — means insiders have been distributing at every price point available during the recovery. Vanguard and BlackRock both added to their positions in recent filings, and LB Partners entered as a new holder with 893,500 shares in the most recent quarter, providing some institutional ballast.
The next confirmed event is May 20 — worth watching to see whether the post-Q1 short unwind continues or whether bears use the looser borrow conditions and available supply to rebuild exposure ahead of what has historically been a volatile reporting cycle for SPT.
See the live data behind this article on ORTEX.
Open SPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
